For Healthcare Professionals

FIRAZYR General Drug Use-Results Survey (Japan)

clipboard-pencil

About the study

The objectives of this survey are to collect data to report the safety and efficacy of Firazyr (Icatibant acetate) in the post-marketing phase in participants diagnosed with Hereditary Angioedema (HAE).
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Hereditary angioedema (HAE) participants in Japan who receive FIRAZYR for first time in the real world clinical setting.

EXCLUSION CRITERIA

    pin location

    Study Locations

    Enter your ZIP code/Postal code/PIN code to locate study sites near you:

    How to Apply


    Contact the study center to learn if this study is a good match for you.
    Phone iconCall +1 866 842 5335Email iconEmail Study Center

    Study’s details


    Contition

    Hereditary Angioedema (HAE)

    Age

    0+

    Participants needed

    75

    Est. Completion Date

    Nov 2022

    Treatment type

    Observational


    Sponsor

    Takeda

    ClinicalTrials.gov identifier

    NCT04057131

    Study number

    SHP667-401

    Understanding Clinical Trials


    Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
    Vector

    Interested?

    Sign up to save your favorites, 
    receive newsletters, resources, and alerts 
    about clinical trials related to your conditions of interest.